Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Antonio B., Keeton, Adam B., Chen, Xi, Mattox, Tyler E., Coley, Alex B., Maxuitenko, Yulia Y., Buchsbaum, Donald J., Randall, Troy D., Zhou, Gang, Piazza, Gary A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567124/
https://www.ncbi.nlm.nih.gov/pubmed/33073260
http://dx.doi.org/10.1002/mco2.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567124/
https://www.ncbi.nlm.nih.gov/pubmed/33073260
http://dx.doi.org/10.1002/mco2.10

Ejemplares similares